创伤性颅内出血后抗凝药物的使用
回顾性分析本机构3年内因创伤性颅内出血住院并接受静脉肝素、足量依诺肝素或华法林抗凝治疗的112例患者,中位年龄50.5岁、中位格拉斯哥昏迷评分9.5分,伤后至启动抗凝中位时间8天;6例出现即刻并发症但无需神经外科干预,2例迟发性硬膜下血肿进展需干预,1例死于迟发性出血。
要点
- 创伤性颅内出血后启动抗凝需权衡即刻与迟发颅内出血风险及延迟治疗所致并发症。
- 112例中54例在启动抗凝前已发生深静脉血栓或肺栓塞,另20例存在基础疾病或其他抗凝指征。
- 伤后至启动抗凝中位时间8天;即刻并发症6例,均无需神经外科干预。
核心结论
- 对该患者人群,启动抗凝治疗所致即刻与迟发颅内出血风险须与延迟治疗的并发症风险相权衡。
- 作者指出虽需进一步研究,本回顾提供了该患者人群的首批并发症发生率。
研究设计与样本
- 回顾性识别本机构3年内因创伤性颅内出血住院且在初次住院期间接受静脉肝素、足量依诺肝素或华法林治疗的全部患者。
- 共纳入112例患者,中位年龄50.5岁,中位格拉斯哥昏迷评分9.5分。
主要发现
- 22例因就诊损伤需神经外科操作,包括颅内压监测和/或开放手术。
- 54例在启动抗凝前已发生深静脉血栓或肺栓塞,其余20例存在基础疾病或其他启动抗凝的指征。
- 伤后至启动抗凝的中位时间为8天。
- 6例发生即刻并发症,但均无需神经外科干预。
- 迟发并发症包括急性硬膜下血肿进展为慢性硬膜下血肿并需干预2例;1例死于迟发性出血。
局限性
- 作者指出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anticoagulant therapy (ACT) after traumatic intracranial hemorrhage may lead to progression of hemorrhage, but in the presence of thromboembolic events, the clinician must decide if the benefits outweigh the risks. Currently, no data exist to guide therapy in the acute setting. METHODS: We retrospectively identified all patients admitted to our institution with traumatic intracranial hemorrhage that received intravenous heparin, full-dose enoxaparin, or warfarin during their initial hospitalization over a 3-year period. We reviewed their demographics, hospital course, clinical indication and timing for initiation of ACT, and complications. RESULTS: A total of 112 patients were identified. The median age and Glasgow Coma Scale score of these patients was 50.5 years and 9.5, respectively. Twenty-two patients required neurosurgical procedures for their presenting injury, including intracranial pressure monitors and/or open surgeries. Fifty-four patients had deep vein thrombosis or pulmonary embolism prior to initiation, and the remaining 20 patients had preexisting conditions or other indications for initiating ACT. The median time from injury to starting ACT was 8 days. Immediate complications occurred in 6 patients; however, none of these patients required a neurosurgical intervention. Delayed complications included progression of acute to chronic subdural hematoma that required intervention in 2 patients. One patient died from delayed hemorrhage. CONCLUSIONS: For this patient population, the risk of immediate and delayed intracranial hemorrhages from initiating ACT therapy in intracranial injury must be weighed against the morbidity of delaying treatment. Although further studies are needed, our review provides the first rates of complications for this patient population.
引用
- Divito A, Kerr K, Wilkerson C, et al. Use of Anticoagulation Agents After Traumatic Intracranial Hemorrhage. World Neurosurg. 2018. PMID: 30528524. doi:10.1016/j.wneu.2018.10.173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。